Prelude Therapeutics (PRLD)
(Delayed Data from NSDQ)
$0.85 USD
+0.01 (1.01%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $0.85 0.00 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PRLD 0.85 +0.01(1.01%)
Will PRLD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PRLD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRLD
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know
After Plunging -31.47% in 4 Weeks, Here's Why the Trend Might Reverse for Prelude Therapeutics (PRLD)
PRLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD)
Other News for PRLD
Prelude Therapeutics Advances PRT3789 in Phase 1 Study for SMARCA4 Mutant Tumors
Prelude Therapeutics Advances Cancer Treatment with New Phase 2 Study
Tracking Baker Brothers Portfolio - Q1 2025 Update
Baker Bros. Advisors LP Increases Stake in Prelude Therapeutics Inc.
Prelude Therapeutics Appoints Paul Scherer as Director